Harrow's Q3 2026: Revenue Surges, Guidance Recalibrated, and a G‑MELT NDA on Deck

Company: Harrow (ticker: HROW). This earnings release emphasizes revenue strength and non‑GAAP improvements, with limited detail on EPS and no stated EPS consensus in the report. Investors will be watching for actual EPS and how the revenue forecast translates into earnings power.

Executive snapshot: strong top line, mixed bottom line, and a new guidance posture

Harrow reported a robust third quarter, with total revenue of $99.3 million, up 41% sequentially and 39% year over year. Branded revenue accounted for about 84% of the total at $83.5 million, signaling continued momentum in the company’s core product set. GAAP net income reached $9.8 million, helped by a $5.0 million litigation settlement gain, contrasting with a loss in Q2 2026 and a modest profit in Q3 2025. Adjusted EBITDA was $21.2 million, a meaningful swing from Q2, and roughly flat to the year-ago period on a non‑GAAP basis.

On the numerical front, the report does not include an EPS figure or an EPS consensus. The focus shifts to revenue drivers and non‑GAAP profitability. The company reaffirmed its full-year revenue forecast of $350 million to $365 million, while dramatically updating its Adjusted EBITDA target to more than $40 million for 2026, with fourth-quarter Adjusted EBITDA expected to exceed $33 million. By contrast, the prior guidance spanned $80 million to $100 million in Adjusted EBITDA, suggesting a material reshaping of the profitability trajectory alongside the revenue outlook.

Cash and cash equivalents stood at $75.3 million as of September 30, 2026. Management framed the revision as reflecting mix and timing of investments and milestones rather than a shift in long‑term strategy.

Business highlights by engine: VEVYE, TRIESENCE, IHEEZO, and near-term tailwinds

The quarterly narrative centers on branded growth and multi‑product momentum. Highlights include:

VEVYE revenue of $39.7 million, up 35% sequentially and 75% year over year. The growth is supported by rising prescriptions and expanding coverage.
Expanded payer coverage, now including a major national plan representing 10+ million commercial lives, with implementation anticipated January 2027.
Operations and pipeline: the company points to continued prescription growth, productivity gains from an expanded sales force, and strong demand for branded offerings.
TRIESENCE and IHEEZO contributed to the quarter’s strength, with IHEEZO noted as part of ongoing demand momentum. TYRVAYA is highlighted as a contributor beginning in the near term, signaling potential upside from newer products.

Management perspective and strategic read-through

In remarks attributed to Mark L. Baum, Chairman and Chief Executive Officer, Harrow frames Q3 as the point where a second-half acceleration began to take shape. He cites branded product demand, VEVYE growth, and TRIESENCE as levers driving the quarterly performance, while signaling optimism for TYRVAYA’s initial revenue contribution and the potential for IHEEZO to sustain its growth trajectory.

The forward-looking tone acknowledges that achieving the full-year revenue targets will require sustained execution. The adjusted EBITDA revision, described as a floor rather than a cap, implies management wants to leave room for upside, yet acknowledges the near-term margin challenge embedded in accelerating development programs and regulatory activities (notably the G‑MELT NDA submission) and the integration of TYRVAYA.

Guidance and what it portends for the sector

The guidance refresh is the core market signal. Harrow now targets:

Revenue forecast for 2026: $350 million to $365 million.
Adjusted EBITDA for 2026: more than $40 million, including Q4 Adjusted EBITDA above $33 million.
Previously, the company had guided Adjusted EBITDA in the range of $80 million to $100 million, underscoring a sizable recalibration of profitability expectations alongside the revenue plan.

The emphasis on VEVYE’s payer expansion and the anticipation of TYRVAYA’s revenue contribution suggest a pivot toward broader market access and a deeper line‑extension strategy. The 10+ million commercial lives coverage could provide a near‑term accelerant for branded revenue, while regulatory and development costs (G‑MELT NDA) may press on cash flow in the near term.

What this implies for Harrow and peers

For Harrow, the narrative is twofold. First, it demonstrates substantial top‑line growth fueled by branded products and a widening payer base. Second, it reveals a management team that is willing to recalibrate profitability targets in the face of pipeline investments and regulatory milestones. The mismatch between the revenue forecast and the EBITDA guidance invites a closer look at margin structure, product mix, and the pace of commercialization for newer offerings.

Sector peers in ophthalmology and disease management will be watching several levers here: how rapidly branded products can convert into durable revenue streams, how payer coverage translates into real-world utilization, and how regulatory timelines (like G‑MELT NDA submissions) compress or stretch profitability in the near term. The emphasis on non‑GAAP measures—Adjusted EBITDA in particular—will remain a critical lens for evaluating whether Harrow’s operating leverage can outpace spending in development and market access.

Context on earnings metrics

Note for readers tracking traditional earnings metrics: the release does not provide an EPS figure or an explicit EPS consensus. The headline and most of the discussion center on revenue, gross dynamics, and Adjusted EBITDA. The absence of a stated EPS and consensus means investors will infer profit quality primarily from non‑GAAP profitability and the trajectory of cash generation rather than a clean per‑share result in this quarter.

In practice, traders may weigh Harrow’s EPS potential against the revenue forecast and the push toward higher-margin branded revenue. The company’s approach—pushing for caps on EBITDA driven by large strategic investments and regulatory milestones—renders “earnings surprise” less straightforward than in a simple beat‑or‑miss scenario. Still, the shift in guidance and the ability to deliver meaningful Q4 profitability will influence how the street gauges EBITDA versus the traditional EPS narrative.

Closing thoughts: a turning point or a recalibration?

Harrow’s Q3 2026 results present a carefully balanced picture: impressive revenue growth and a meaningful one‑time gain supporting net income, tempered by a recalibrated profitability outlook. The company’s strategy hinges on converting payer expansions and new product introductions into durable revenue streams, while managing the cost and regulatory cadence of pipeline programs like the G‑MELT NDA submission.

For investors, the next milestones to watch are the realization of the January 2027 payer coverage expansion, the ramp of TYRVAYA’s revenue contribution, and the trajectory of Q4 profitability that would anchor the new >$40 million Adjusted EBITDA target. If Harrow can translate the improved top line into consistent EBITDA gains and deliver a credible EPS path, the period of adjustment may be viewed as a necessary pivot—one that separates durable growth from temporary gains.